Atara Biotherapeutics Presents Positive Efficacy and Safety Results
Atara Biotherapeutics reported results indicating that tab-cel® (tabelecleucel) was generally well tolerated with responses for patients with Epstein-Barr virus-associated leiomyosarcoma. EBV+ LMS is a rare soft tissue sarcoma that occurs in transplant and immunosuppressed patients. December 15, 2018